JP2017514877A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514877A5
JP2017514877A5 JP2016567002A JP2016567002A JP2017514877A5 JP 2017514877 A5 JP2017514877 A5 JP 2017514877A5 JP 2016567002 A JP2016567002 A JP 2016567002A JP 2016567002 A JP2016567002 A JP 2016567002A JP 2017514877 A5 JP2017514877 A5 JP 2017514877A5
Authority
JP
Japan
Prior art keywords
methoxycyclopent
group
similarly
described below
same structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567002A
Other languages
English (en)
Japanese (ja)
Other versions
JP6505131B2 (ja
JP2017514877A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2015/051312 external-priority patent/WO2015170081A1/en
Publication of JP2017514877A publication Critical patent/JP2017514877A/ja
Publication of JP2017514877A5 publication Critical patent/JP2017514877A5/ja
Application granted granted Critical
Publication of JP6505131B2 publication Critical patent/JP6505131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567002A 2014-05-08 2015-05-05 イミダゾ[4,5−c]キノリン−2−オン化合物および癌の処置におけるそれらの使用 Active JP6505131B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990232P 2014-05-08 2014-05-08
US61/990,232 2014-05-08
PCT/GB2015/051312 WO2015170081A1 (en) 2014-05-08 2015-05-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
JP2017514877A JP2017514877A (ja) 2017-06-08
JP2017514877A5 true JP2017514877A5 (enFirst) 2018-06-14
JP6505131B2 JP6505131B2 (ja) 2019-04-24

Family

ID=53264681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567002A Active JP6505131B2 (ja) 2014-05-08 2015-05-05 イミダゾ[4,5−c]キノリン−2−オン化合物および癌の処置におけるそれらの使用

Country Status (39)

Country Link
US (4) US9428503B2 (enFirst)
EP (1) EP3140303B1 (enFirst)
JP (1) JP6505131B2 (enFirst)
KR (1) KR102013021B1 (enFirst)
CN (1) CN106255692B (enFirst)
AP (1) AP2016009532A0 (enFirst)
AR (1) AR100340A1 (enFirst)
AU (1) AU2015257456B2 (enFirst)
CA (1) CA2946459C (enFirst)
CL (1) CL2016002735A1 (enFirst)
CR (1) CR20160523A (enFirst)
CY (1) CY1120248T1 (enFirst)
DK (1) DK3140303T3 (enFirst)
DO (1) DOP2016000281A (enFirst)
EA (1) EA031674B1 (enFirst)
ES (1) ES2670416T3 (enFirst)
HR (1) HRP20180697T1 (enFirst)
HU (1) HUE037558T2 (enFirst)
IL (1) IL248397B (enFirst)
LT (1) LT3140303T (enFirst)
MA (1) MA39960A (enFirst)
MX (1) MX374401B (enFirst)
NI (1) NI201600166A (enFirst)
NO (1) NO2714752T3 (enFirst)
NZ (1) NZ726042A (enFirst)
PE (1) PE20170403A1 (enFirst)
PH (1) PH12016502168A1 (enFirst)
PL (1) PL3140303T3 (enFirst)
PT (1) PT3140303T (enFirst)
RS (1) RS57223B1 (enFirst)
SG (1) SG11201609164VA (enFirst)
SI (1) SI3140303T1 (enFirst)
SM (1) SMT201800259T1 (enFirst)
SV (1) SV2016005312A (enFirst)
TN (1) TN2016000458A1 (enFirst)
TR (1) TR201807101T4 (enFirst)
TW (1) TWI662034B (enFirst)
UY (1) UY36112A (enFirst)
WO (1) WO2015170081A1 (enFirst)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3277681T3 (pl) * 2015-04-02 2019-10-31 Merck Patent Gmbh Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2017142871A1 (en) * 2016-02-15 2017-08-24 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
PE20181895A1 (es) * 2016-03-21 2018-12-11 Astrazeneca Ab Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer
US20190119270A1 (en) 2016-04-07 2019-04-25 Astrazeneca Ab N-Oxide Compound and Its Use in Treating Cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
DK3558997T3 (da) 2016-12-20 2021-04-19 Astrazeneca Ab Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
US10874670B2 (en) 2017-01-09 2020-12-29 Impact Therapeutics, Inc. Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof
CN106798741A (zh) * 2017-02-07 2017-06-06 宫英 一种治疗抑郁症的药物组合物
CN106692147A (zh) * 2017-02-07 2017-05-24 李明英 一种治疗男性不育的药物组合物
CN106822123A (zh) * 2017-02-09 2017-06-13 王艳苓 一种治疗心脑血管疾病的药物组合物
WO2018153365A1 (zh) 2017-02-27 2018-08-30 上海瑛派药业有限公司 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2020052688A1 (en) * 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF
JP2022505041A (ja) * 2018-10-15 2022-01-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Dnaアルキル化剤及びatr阻害剤を使用する併用療法
ES3010507T3 (en) * 2019-03-05 2025-04-03 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
TW202102497A (zh) * 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
CN111909147B (zh) * 2019-05-10 2021-07-20 山东轩竹医药科技有限公司 Dna-pk抑制剂
WO2021004482A1 (zh) * 2019-07-10 2021-01-14 上海瑛派药业有限公司 取代的吡唑并喹唑啉酮化合物及其应用
EP4028400A4 (en) 2019-09-12 2023-09-06 Impact Therapeutics (Shanghai), Inc Substituted imidazoquinoxaline compounds and uses thereof
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021146127A1 (en) * 2020-01-13 2021-07-22 Zhanggui Wu Use of n2-quincline or isoquinoline substituted purine derivatives in cancer treatment
CN116194109A (zh) * 2020-06-24 2023-05-30 阿斯利康(英国)有限公司 抗体-药物缀合物和atm抑制剂的组合
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CN117015534A (zh) * 2021-02-03 2023-11-07 艾科思莱德制药公司 用于癌症疗法的双重atm和dna-pk抑制剂以及免疫治疗剂的组合
AU2021433713A1 (en) 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN118434736A (zh) * 2022-01-26 2024-08-02 正大天晴药业集团股份有限公司 含有肼基的化合物
CN117756799A (zh) * 2022-09-23 2024-03-26 四川大学华西医院 一种化合物及其在制备atm激酶抑制剂中的用途
CN121038817A (zh) 2023-04-10 2025-11-28 第一三共株式会社 抗-b7-h3抗体-药物缀合物和atr抑制剂或atm抑制剂的组合

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
US8791131B2 (en) 2008-09-30 2014-07-29 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
MA33332B1 (fr) 2009-06-04 2012-06-01 Novartis Ag Dérivés de la 1h-imidazo[4,5-c]quinolinone
CN102803259A (zh) * 2009-06-04 2012-11-28 诺瓦提斯公司 用于治疗增殖性疾病的1H-咪唑并[4,5-c]喹啉酮化合物
US8263633B2 (en) * 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
WO2012026233A1 (ja) 2010-08-26 2012-03-01 日立建機株式会社 建設機械
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药(上海)有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
AR084731A1 (es) 2010-12-06 2013-06-05 Piramal Life Sciences Ltd Derivados de imidazoquinolina sustituidos
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Similar Documents

Publication Publication Date Title
JP2017107167A5 (enFirst)
JP2017016753A5 (enFirst)
JP2014179090A5 (enFirst)
JP2017059339A5 (enFirst)
JP2016204575A5 (enFirst)
JP2015077594A5 (enFirst)
JP2017528346A5 (enFirst)
JP2017069240A5 (enFirst)
JP2017528401A5 (enFirst)
JP2017179103A5 (enFirst)
JP2017509780A5 (enFirst)
JP2017533170A5 (enFirst)
JP2016169268A5 (enFirst)
JP2016069397A5 (enFirst)
JP2017203885A5 (enFirst)
JP2019505548A5 (enFirst)
JP2017020017A5 (enFirst)
JP2018538325A5 (enFirst)
JP2016157119A5 (enFirst)
JP2017075254A5 (enFirst)
JP2016172836A5 (enFirst)
JP2016074795A5 (enFirst)
JP2015174850A5 (enFirst)
JP2017105890A5 (enFirst)
JP2016210942A5 (enFirst)